Patents by Inventor Peter C. Baciu

Peter C. Baciu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20210101965
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 8, 2021
    Inventors: Peter C. BACIU, Yanbin LIANG, Jason GUU, Matthew BERNETT, Umesh MUCHHAL, John DESJARLAIS
  • Complement component C5 antibodies
    Patent number: 10752678
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 25, 2020
    Assignees: ALLERGAN, INC., XENCOR, INC.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20180222969
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Nucleic acids encoding complement component C5 antibodies
    Patent number: 9932395
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 3, 2018
    Assignees: Allergan, Inc., Xencor, Inc.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20170306007
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 26, 2017
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Complement component C5 antibodies
    Patent number: 9701743
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 11, 2017
    Assignee: Allergan, Inc.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20150239966
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: February 19, 2015
    Publication date: August 27, 2015
    Applicant: XENCOR, INC.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20130237602
    Abstract: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.
    Type: Application
    Filed: April 15, 2013
    Publication date: September 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Wendy M. Blanda, Patrick M. Hughes, Peter C. Baciu
  • VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20120059060
    Abstract: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.
    Type: Application
    Filed: November 16, 2011
    Publication date: March 8, 2012
    Inventors: Wendy M. Blanda, Patrick M. Hughes, Peter C. Baciu
  • NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE
    Publication number: 20110269807
    Abstract: The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need.
    Type: Application
    Filed: April 29, 2011
    Publication date: November 3, 2011
    Applicant: ALLERGAN, INC.
    Inventor: Peter C. Baciu
  • VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF
    Publication number: 20100204325
    Abstract: Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.
    Type: Application
    Filed: February 11, 2009
    Publication date: August 12, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Wendy M. Blanda, Patrick M. Hughes, Peter C. Baciu
  • Two novel genes from psoriatic epidermis: psoriastatin type I and psoriastatin type II
    Patent number: 6818214
    Abstract: A method of modulating cell proliferation or apoptosis comprising modulating psoriastatin activity.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: November 16, 2004
    Assignees: The General Hospital Corporation, Shiseido Co., Ltd.
    Inventors: Toshihiko Hibino, Tadahito Takahashi, Peter C. Baciu, Paul F. Goetinck
  • Methods of screening and using inhibitors of angiogenesis
    Publication number: 20040126825
    Abstract: A method of screening for agents which are able to inhibit angiogenesis. Such agent have therapeutic application in the treatment of conditions including cancer, macular degeneration and retinopathies. Also included are methods of treating a patient having a pathological condition characterized by an increase in angiogenesis which comprises administering to the patient an agent capable of inhibiting activation of an integrin subunit.
    Type: Application
    Filed: October 29, 2003
    Publication date: July 1, 2004
    Applicant: Allergan, Inc
    Inventors: Peter C. Baciu, Heying Zhang, Virna M. Manuel
  • Methods of screening and using inhibitors of angiogenesis
    Publication number: 20030171271
    Abstract: A method of screening for agents which are able to inhibit angiogenesis. Such agent have therapeutic application in the treatment of conditions including cancer, macular degeneration and retinopathies. Also included are methods of treating a patient having a pathological condition characterized by an increase in angiogenesis which comprises administering to the patient an agent capable of inhibiting activation of an integrin subunit.
    Type: Application
    Filed: April 3, 2002
    Publication date: September 11, 2003
    Inventors: Peter C. Baciu, Heying Zhang, Virna M. Manuel
  • Syndecan-4 binding protein (S4BP) and uses thereof
    Patent number: 6566489
    Abstract: The present invention relates to a gene encoding a novel protein, syndecan-4 binding protein (S4BP), which binds to syndecan-4. S4BP polypeptides play a role in cell matrix interactions. Described herein are isolated and antisense nucleic acids molecules, recombinant expression vectors, host cells and non-human transgenic animals containing an insertion or a disruption of the S4BP gene. Diagnostic, screening and therapeutic methods utilizing the compositions of the invention are also provided.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: May 20, 2003
    Assignee: The General Hospital Corporation
    Inventors: Paul F. Goetinck, Peter C. Baciu
  • TWO NOVEL GENES FROM PSORIATIC EPIDERMIS: PSORIASTATIN TYPE I AND PSORIASTATIN TYPE II
    Publication number: 20030072752
    Abstract: A method of modulating cell proliferation or apoptosis comprising modulating psoriastatin activity.
    Type: Application
    Filed: October 16, 1996
    Publication date: April 17, 2003
    Applicant: General Hospital Corporation, a Massachusetts corporation
    Inventors: TOSHIHIKO HIBINO, TADAHITO TAKAHASHI, PETER C. BACIU, PAUL F. GOETINCK